Thrive Launches with $110 Million Series A Financing to Integrate Earlier Detection of Multiple Cancer Types into Routine Medical Care

Company Advancing CancerSEEK, A DNA- and Protein-based Liquid Biopsy Test Developed by The Vogelstein Lab at Johns Hopkins University

10,000 Person Prospective Trial Fully Enrolled with Geisinger; Financing Will Support Expanded Clinical Development to Enable Regulatory Approvals and Broad Reimbursement Access

Company Will Integrate Real-World Data and Machine Learning to Enable a Comprehensive Care Solution for Primary Care Physicians

Third Rock Ventures Led Financing Together with Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, Invus, Exact Sciences and …